MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Vaccine against HER2-positive breast cance

Back to society news Blogs list Cancer blog  


Subscribe To Society News RSS Feed  RSS content feed What is RSS feed?

Vaccine against HER2-positive breast cance




Scientists at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 treatment - without any toxicity.

The study, published in the September 15 issue of Cancer Research, a journal of the American Association for Cancer Research, suggests the vaccine could treat women with HER2-positive, therapy-resistant cancer or help prevent cancer recurrence. The scientists also say it might potentially be used in cancer-free women to prevent initial development of these tumors.



Vaccine against HER2-positive breast cance

HER2 receptors promote normal cell growth, and are found in low amounts on normal breast cells. But HER2-positive breast cells can contain a number of more receptors than is typical, promoting a especially aggressive type of tumor that affects 20 to 30 percent of all patients with breast cancer. Therapies such as trastuzumab and lapatinib, designed to latch on to these receptors and destroy them, are a mainstay of therapy for this cancer, but a significant proportion of patients develop a resistance to them or cancer metastasis that is hard to treat.

This therapy relied on activated, own-immunity to wipe out the cancer, says the study's lead investigator, Wei-Zen Wei, Ph.D., a professor of immunology and microbiology at the Karmanos Cancer Institute.

"The immune response against HER2-positive receptors we saw in this study is powerful, and works even in tumors that are resistant to current therapies," she said. "The vaccine could potentially eliminate the need to even use these therapies".

The vaccine consists of "naked" DNA genes that produce the HER2 receptor as well as an immune stimulant. Both are housed within an inert bacterial plasmid. In this study, the scientists used pulses of electricity to deliver the injected vaccine into leg muscles in mice, where the gene produced a huge quantity of HER2 receptors that activated both antibodies and killer T cells.

"While HER2 receptors are not commonly seen by the immune system when they are expressed at low level on the surface of normal cells, a sudden flood of receptors alerts the body to an invasion that needs to be eliminated," Wei said. "During that process, the immune system learns to attack cancer cells that display large numbers of these receptors".

They also used an agent that, for a while, suppressed the activity of regulatory T cells, which normally keeps the immune system from over-reacting. In the absence of regulatory T cells, the immune system responded much more strongly to the vaccine. Then, when the scientists implanted HER2-positive breast tumors in the animals, the cancer was eradicated.

"Both tumor cells that respond to current targeted therapies and those that are resistant to these therapys were eradicated," Wei said. "This may be an answer for women with these tumors who become resistant to the current therapies." .

Wei's lab is the first to develop HER2 DNA vaccines, and this is the second such vaccine Wei and her colleagues have tested more extensively. The first, described in a study in 1999, formed the model of a vaccine now being tested by a major Pharmaceutical company in early phase clinical trials in the U.S. and in Europe in women with HER2-positive breast cancer.

In order to ensure complete safety, Wei says the current test vaccine uses HER2 genes that are altered so that they cannot be oncogenic. The receptors produced do not contain an "intracellular domain" the part of the receptor that is located just below the cell surface and transmits growth signals to the nucleus. The first vaccine was also safe, she says, but contained a little more of the native HER2 receptor structure. "With this vaccine, I am quite certain the receptor is functionally dead," she said.

"The greatest power of vaccination is protection against initial cancer development, and that is our ultimate goal with this therapy," Wei said.


Posted by: Janet    Source




Did you know?
Scientists at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 treatment - without any toxicity. The study, published in the September 15 issue of Cancer Research, a journal of the American Association for Cancer Research, suggests the vaccine could treat women with HER2-positive, therapy-resistant cancer or help prevent cancer recurrence. The scientists also say it might potentially be used in cancer-free women to prevent initial development of these tumors.

Medicineworld.org: Vaccine against HER2-positive breast cance

Asthma| Hypertension| Medicine Main| Diab french| Diabetes drug info| DruginfoFrench| Type2 diabetes| Create a dust free bedroom| Allergy statistics| Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.